Parkinson's stem-cell success claims vary widely across uncontrolled trials — some report motor-score 'improvement' in a portion of patients, others minimal change. No placebo-controlled trial has set a consensus rate. Reported gains are usually modest (small reductions in tremor or rigidity on rating scales) and do not equal major functional independence. Distinguishing effect from natural fluctuation or concurrent levodopa is problematic.
Sixty-nine registered trials and 16 recruiting studies investigate stem-cell approaches in Parkinson's. Small series document modest motor-symptom changes within 6–12 months, but are typically unblinded, single-arm, and lack sham controls. A few report dopamine-replacement activity on PET imaging; durability beyond 12 months is sparse. Heterogeneous cell products and delivery routes complicate interpretation. No trial has prevented progression or restored motor function to pre-disease levels.
האם אני מועמד? → · Parkinson's Disease: full overview → · עלות מחלת פרקינסון → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם